| gap-pubmed-20260410- | What determines the context-dependent therapeutic potential across the multiple | open | 0.71 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does FGF2 simultaneously promote beneficial remyelination and detrimental ne | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Can sphingolipid metabolites serve as early biomarkers for neurodegenerative dis | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do sphingolipids regulate exosomal clearance versus spread of neurotoxic pro | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link early ceramide/S1P alterations to amyloid β and α-synuclein | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does Tet2 expression decrease in AD brains despite its apparent neuroprotect | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms mediate Tet2's neuroprotective effects against Aβ42 to | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do peripheral pathway interventions modify AD risk or progression through pl | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What unknown factors account for half of cognitive decline-associated proteins b | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What peripheral mechanisms contribute to AD neuropathologies independent of brai | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What drives the heterogeneity in cerebral atrophic rates among MCI patients with | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms explain why microglia proteins have opposite cognitive effects i | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Which of the 68 affected N-myristoylated proteins are primary drivers of the neu | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does ACBD6 deficiency cause progressive movement disorders while ACBD5 defic | open | 0.78 | 0.00 | 2026-04-10 | 0 | | movement-disorders |
| gap-pubmed-20260410- | How does ACBD6 deficiency mechanistically cause the specific pattern of midline | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | Does restoring neuronal AMPK activity reverse microglial inflammation in vivo? | partially_addressed | 0.87 | 0.00 | 2026-04-10 | 1 | 2026-04-25 | neurodegeneration |
| gap-pubmed-20260410- | How do lipid droplets in microglia trigger proinflammatory activation? | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms mediate AMPK-controlled lipid efflux from neurons? | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do transient tau interactions detected by BioID2 but missed by co-IP contrib | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which of the 324 identified tau interactors are functionally relevant versus pro | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms determine tau's compartment-specific interactions across cytoske | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do these BDNF-mediated neuroprotective effects translate from dissociated cultur | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the timing and dosage of BDNF administration affect neuroprotection in | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific downstream molecular mechanisms by which BDNF/TrkB signali | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do genetic factors like APOE ε4 mechanistically link BBB dysfunction to amyl | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why have BBB-targeted therapeutic strategies failed to translate into effective | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether BBB dysfunction is a trigger, bystander, or consequence | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do exercise-activated periventricular NSCs functionally integrate and improve co | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does exercise selectively benefit aged mice (≥18 months) but not younger ani | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the molecular mechanisms by which growth hormone activates periventricu | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the biological impacts of SOD1 transmission from motor neurons to naïve | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the precise molecular mechanisms by which P2X7 receptor activation trig | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does ApoE4 reduction simultaneously decrease neuroinflammation and preserve | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Would ApoE4 reduction be therapeutically effective in human tauopathies beyond t | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms mediate ApoE4's promotion of tau pathology and neurode | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do COPD patients specifically develop premature endothelial senescence compa | open | 0.76 | 0.00 | 2026-04-10 | 0 | | vascular-biology |
| gap-pubmed-20260410- | What molecular mechanisms link telomere dysfunction to inflammatory cytokine pro | open | 0.82 | 0.00 | 2026-04-10 | 0 | | cellular-senescence |
| gap-pubmed-20260410- | How do ventral subiculum neurons functionally integrate with hippocampal-entorhi | open | 0.77 | 0.00 | 2026-04-10 | 0 | | spatial-memory |
| gap-pubmed-20260410- | What mechanisms cause ventral subiculum lesions to trigger selective neurodegene | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does IFN-γ have unique microglial activation properties compared to other pr | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the precise molecular mechanisms linking moderate nitric oxide release | open | 0.82 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How does IFN-γ priming specifically drive TLR-activated microglia into neurotoxi | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does cAMP elevation specifically regulate AnxA1 expression at the transcript | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the downstream molecular mechanisms by which PKA-phosphorylated AnxA1 i | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do locomotion signals reach barrel cortex to modulate activity in the absenc | resolved | 0.73 | 0.00 | 2026-04-10 | 0 | | sensorimotor-neuroscience |
| gap-pubmed-20260410- | What cellular mechanisms drive the layer-specific differences in touch response | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | sensorimotor-neuroscience |
| gap-pubmed-20260410- | Does INPP5D-RIPK1 interaction regulate other neurodegenerative diseases beyond A | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the specificity of RIPK1-mediated transcriptional programs in di | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does microglial INPP5D deficiency non-cell-autonomously induce neuronal TDP- | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What structural changes occur in Tau upon S404 phosphorylation that enable the o | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |